Please use this identifier to cite or link to this item:
https://dipositint.ub.edu/dspace/handle/2445/205747
Title: | Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly |
Author: | Marques Pamies, Montserrat Gil, Joan Valassi, Elena Hernández, Marta Biagetti, Betina Giménez Palop, Olga Martínez, Silvia Carrato, Cristina Pons, Laura Villar Taibo, Rocío Araujo Castro, Marta Blanco, Concepción Simón, Inmaculada Simó Servat, Andreu Xifra, Gemma Vázquez, Federico Pavón, Isabel García Centeno, Rogelio Zavala, Roxana Hanzu, Felicia Alexandra Mora, Mireia Aulinas, Anna Vilarrasa, Nuria Librizzi, Soledad Calatayud, María De Miguel, Paz Alvarez Escola, Cristina Picó, Antonio Sampedro, Miguel Salinas, Isabel Fajardo Montañana, Carmen Cámara, Rosa Bernabéu, Ignacio Jordà, Mireia Webb, Susan M. Marazuela, Mónica Puig Domingo, Manel |
Issue Date: | 31-Oct-2023 |
Publisher: | Frontiers Media SA |
Abstract: | Introduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .Methods: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was >= 3SDS, were considered non-responders. The 2 hours GH value (GH2h) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively.Results: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 +/- 4.2 vs 3.3 +/- 2.1; p=0.01).Conclusion: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fendo.2023.1269787 |
It is part of: | Frontiers in Endocrinology, 2023, vol. 14 |
URI: | http://hdl.handle.net/2445/205747 |
Related resource: | https://doi.org/10.3389/fendo.2023.1269787 |
ISSN: | 1664-2392 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fendo-14-1269787.pdf | 1.41 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License